Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
Aliso Viejo, CA, January 28, 2008 - Ambry Genetics, a recognized leader in comprehensive clinical genetic testing, has created a new division to support Pharmaceutical Research, Clinical Research Organizations (CROs) and Clinical Trials.
The role that genetics is taking in drug development and Clinical Trials is expanding as new technologies enable rapid analysis of genetic causes of drug response and toxicity. An individual’s genetic make-up can have a significant impact on how they respond to certain drugs. Ambry Genetics has created a separate division focused on providing genetic testing and bio-informatics to researchers.
Ambry Genetics has the capabilities to perform SNP analysis, custom mutation panels, drug metabolism panels, full gene sequencing, genome sequencing and gene expression analysis. Testing can be performed at all levels of regulatory compliance from basic research, GLP compliant to clinical testing in our CLIA Licensed and CAP Accredited laboratory.
Ambry’s President & CEO, Charles L.M. Dunlop, explains: "Ambry has supported Pharmaceutical Research and Clinical Trials with genetic testing for many years. The creation of this division will allow us to have a focused team approach to helping solve the complex genetic questions in drug development and Clinical Trials management. We have made significant investment in state of art technology and bio-informatics to ensure our Pharmaceutical Services clients enjoy the same world class service as our diagnostic clients."
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com